Making it two out of three, AbbVie Inc.'s Rinvoq met all key endpoints in its second Phase III Measure Up study, evaluating the JAK1 inhibitor’s potential as a once-daily oral treatment for atopic dermatitis.
AbbVie on 21 July said the compound, which was approved in the US and Europe in 2019 to treat certain...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
